The study titled “Treatment of early-onset fetal growth restriction with low molecular weight heparin does not prolong gestation: a randomized clinical trial” investigated the effectiveness of low molecular weight heparin (LMWH) in prolonging pregnancy in cases of early-onset fetal growth restriction (FGR).
This was a phase III, multicenter, triple-blind, parallel-arm randomized clinical trial conducted in two university hospitals in Spain. Forty-nine patients with singleton pregnancies diagnosed with early-onset FGR were included. Twenty-three patients received subcutaneous bemiparin (LMWH) at a prophylactic dose, and 26 received a placebo from diagnosis until delivery.
The primary outcomes measured were the prolongation of pregnancy from inclusion to live birth (days) and gestational age at live birth (days).
Key Findings
Conclusion
The study concluded that the use of prophylactic dose LMWH (bemiparin) started at the time of diagnosis does not prolong pregnancy in individuals with early-onset FGR. Therefore, its use is not justified as a standard treatment for this condition. The authors suggest that further research is needed to explore alternative therapies and interventions for early-onset FGR that may prolong gestational age at delivery and improve perinatal outcomes.
study shows that prophylactic low molecular weight heparin (LMWH) does not significantly prolong pregnancy in early-onset fetal growth restriction (FGR)
